Heart rate control with oral ivabradine in computed tomography coronary angiography

A randomized comparison of 7.5 mg vs 5 mg regimen

Andrea Igoren Guaricci, Erica Maffei, Natale D. Brunetti, Deodata Montrone, Luigi Di Biase, Carlo Tedeschi, Giovanni Gentile, Luca Macarini, Massimo Midiri, Filippo Cademartiri, Matteo Di Biase

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of oral ivabradine seems to be more effective than beta-blockade in reducing HR in patients referred for CTCA. Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA were prospectively enrolled. Patients not receiving beta-blocker at baseline (group 1) and those with beta-blocker therapy (group 2) were enrolled in the study. Each group was randomized into 3 parallel arms with 1:1:1 allocation. Patients who did not receive beta-blocker at baseline: underwent CTCA without beta blocker (n = 49), and received ivabradine 5 mg (n = 48), or 7.5 mg ivabradine (n = 48). Patients with beta-blocker therapy: continued with the prior beta-blocker without any dose modification (n = 38), and received ivabradine 5 mg (n = 38), or ivabradine 7.5 mg (n = 38). Results: HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). Administration of ivabradine 7.5 mg significantly reduced mean relative HR at T1 and T2 (p <0.01), the rate of patients not achieving target HR at T1 (p <0.001) and T2 (p <0.01), and the percentage of patients needing additional IV beta-blockade prior to CTCA (p <0.01). Results remained statistically significant even after correction for age, gender, ejection fraction, risk factors and HR at T0, in a multivariable analysis. Conclusions: Ivabradine 7.5 mg is more effective than ivabradine 5 mg in increasing the rate of patients at target HR in patients referred for CTCA.

Original languageEnglish
Pages (from-to)362-368
Number of pages7
JournalInternational Journal of Cardiology
Volume168
Issue number1
DOIs
Publication statusPublished - Sep 20 2013

Fingerprint

ivabradine
Coronary Angiography
Heart Rate
Computed Tomography Angiography
Group Psychotherapy

Keywords

  • Computed tomography coronary angiography
  • Coronary heart disease
  • Heart rate reduction
  • Ivabradine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Heart rate control with oral ivabradine in computed tomography coronary angiography : A randomized comparison of 7.5 mg vs 5 mg regimen. / Guaricci, Andrea Igoren; Maffei, Erica; Brunetti, Natale D.; Montrone, Deodata; Di Biase, Luigi; Tedeschi, Carlo; Gentile, Giovanni; Macarini, Luca; Midiri, Massimo; Cademartiri, Filippo; Di Biase, Matteo.

In: International Journal of Cardiology, Vol. 168, No. 1, 20.09.2013, p. 362-368.

Research output: Contribution to journalArticle

Guaricci, AI, Maffei, E, Brunetti, ND, Montrone, D, Di Biase, L, Tedeschi, C, Gentile, G, Macarini, L, Midiri, M, Cademartiri, F & Di Biase, M 2013, 'Heart rate control with oral ivabradine in computed tomography coronary angiography: A randomized comparison of 7.5 mg vs 5 mg regimen', International Journal of Cardiology, vol. 168, no. 1, pp. 362-368. https://doi.org/10.1016/j.ijcard.2012.09.041
Guaricci, Andrea Igoren ; Maffei, Erica ; Brunetti, Natale D. ; Montrone, Deodata ; Di Biase, Luigi ; Tedeschi, Carlo ; Gentile, Giovanni ; Macarini, Luca ; Midiri, Massimo ; Cademartiri, Filippo ; Di Biase, Matteo. / Heart rate control with oral ivabradine in computed tomography coronary angiography : A randomized comparison of 7.5 mg vs 5 mg regimen. In: International Journal of Cardiology. 2013 ; Vol. 168, No. 1. pp. 362-368.
@article{593506790a75434c8fc610a8dd819151,
title = "Heart rate control with oral ivabradine in computed tomography coronary angiography: A randomized comparison of 7.5 mg vs 5 mg regimen",
abstract = "Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of oral ivabradine seems to be more effective than beta-blockade in reducing HR in patients referred for CTCA. Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA were prospectively enrolled. Patients not receiving beta-blocker at baseline (group 1) and those with beta-blocker therapy (group 2) were enrolled in the study. Each group was randomized into 3 parallel arms with 1:1:1 allocation. Patients who did not receive beta-blocker at baseline: underwent CTCA without beta blocker (n = 49), and received ivabradine 5 mg (n = 48), or 7.5 mg ivabradine (n = 48). Patients with beta-blocker therapy: continued with the prior beta-blocker without any dose modification (n = 38), and received ivabradine 5 mg (n = 38), or ivabradine 7.5 mg (n = 38). Results: HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). Administration of ivabradine 7.5 mg significantly reduced mean relative HR at T1 and T2 (p <0.01), the rate of patients not achieving target HR at T1 (p <0.001) and T2 (p <0.01), and the percentage of patients needing additional IV beta-blockade prior to CTCA (p <0.01). Results remained statistically significant even after correction for age, gender, ejection fraction, risk factors and HR at T0, in a multivariable analysis. Conclusions: Ivabradine 7.5 mg is more effective than ivabradine 5 mg in increasing the rate of patients at target HR in patients referred for CTCA.",
keywords = "Computed tomography coronary angiography, Coronary heart disease, Heart rate reduction, Ivabradine",
author = "Guaricci, {Andrea Igoren} and Erica Maffei and Brunetti, {Natale D.} and Deodata Montrone and {Di Biase}, Luigi and Carlo Tedeschi and Giovanni Gentile and Luca Macarini and Massimo Midiri and Filippo Cademartiri and {Di Biase}, Matteo",
year = "2013",
month = "9",
day = "20",
doi = "10.1016/j.ijcard.2012.09.041",
language = "English",
volume = "168",
pages = "362--368",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Heart rate control with oral ivabradine in computed tomography coronary angiography

T2 - A randomized comparison of 7.5 mg vs 5 mg regimen

AU - Guaricci, Andrea Igoren

AU - Maffei, Erica

AU - Brunetti, Natale D.

AU - Montrone, Deodata

AU - Di Biase, Luigi

AU - Tedeschi, Carlo

AU - Gentile, Giovanni

AU - Macarini, Luca

AU - Midiri, Massimo

AU - Cademartiri, Filippo

AU - Di Biase, Matteo

PY - 2013/9/20

Y1 - 2013/9/20

N2 - Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of oral ivabradine seems to be more effective than beta-blockade in reducing HR in patients referred for CTCA. Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA were prospectively enrolled. Patients not receiving beta-blocker at baseline (group 1) and those with beta-blocker therapy (group 2) were enrolled in the study. Each group was randomized into 3 parallel arms with 1:1:1 allocation. Patients who did not receive beta-blocker at baseline: underwent CTCA without beta blocker (n = 49), and received ivabradine 5 mg (n = 48), or 7.5 mg ivabradine (n = 48). Patients with beta-blocker therapy: continued with the prior beta-blocker without any dose modification (n = 38), and received ivabradine 5 mg (n = 38), or ivabradine 7.5 mg (n = 38). Results: HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). Administration of ivabradine 7.5 mg significantly reduced mean relative HR at T1 and T2 (p <0.01), the rate of patients not achieving target HR at T1 (p <0.001) and T2 (p <0.01), and the percentage of patients needing additional IV beta-blockade prior to CTCA (p <0.01). Results remained statistically significant even after correction for age, gender, ejection fraction, risk factors and HR at T0, in a multivariable analysis. Conclusions: Ivabradine 7.5 mg is more effective than ivabradine 5 mg in increasing the rate of patients at target HR in patients referred for CTCA.

AB - Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of oral ivabradine seems to be more effective than beta-blockade in reducing HR in patients referred for CTCA. Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA were prospectively enrolled. Patients not receiving beta-blocker at baseline (group 1) and those with beta-blocker therapy (group 2) were enrolled in the study. Each group was randomized into 3 parallel arms with 1:1:1 allocation. Patients who did not receive beta-blocker at baseline: underwent CTCA without beta blocker (n = 49), and received ivabradine 5 mg (n = 48), or 7.5 mg ivabradine (n = 48). Patients with beta-blocker therapy: continued with the prior beta-blocker without any dose modification (n = 38), and received ivabradine 5 mg (n = 38), or ivabradine 7.5 mg (n = 38). Results: HR and blood pressure were assessed at admission (T0), immediately before CTCA (T1) and during CTCA (T2). Administration of ivabradine 7.5 mg significantly reduced mean relative HR at T1 and T2 (p <0.01), the rate of patients not achieving target HR at T1 (p <0.001) and T2 (p <0.01), and the percentage of patients needing additional IV beta-blockade prior to CTCA (p <0.01). Results remained statistically significant even after correction for age, gender, ejection fraction, risk factors and HR at T0, in a multivariable analysis. Conclusions: Ivabradine 7.5 mg is more effective than ivabradine 5 mg in increasing the rate of patients at target HR in patients referred for CTCA.

KW - Computed tomography coronary angiography

KW - Coronary heart disease

KW - Heart rate reduction

KW - Ivabradine

UR - http://www.scopus.com/inward/record.url?scp=84883763434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883763434&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2012.09.041

DO - 10.1016/j.ijcard.2012.09.041

M3 - Article

VL - 168

SP - 362

EP - 368

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -